Non-invasive detection of a palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats

Cancer Biology and Therapy

Volumn 12, Issue 5, 2011, Pages 399-406

  Yazbeck, Roger ^a,b,c   Howarth, Gordon S ^a,b,c   Borges, Luis ^d   Geier, Mark S ^b,c,e   Smith, Cassie L ^a   Davidson, Geoffrey P ^a   Butler, Ross N ^a,b,c  

^a Children   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d AMGEN INC   (United States)

^e SOUTH AUSTRALIAN RESEARCH AND DEVELOPMENT INSTITUTE   (Australia)

Author keywords

5 fluorouracil; Animal model; Intestine; Keratinocyte growth factor; Mucositis; Palifermin; Sucrose breath test

Indexed keywords

FLUOROURACIL; PALIFERMIN; SODIUM CHLORIDE; SUCRASE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; HISTOLOGY; ILEUM; IN VITRO STUDY; IN VIVO CULTURE; INTESTINE FUNCTION; INTESTINE VILLUS; JEJUNUM; MUCOSA INFLAMMATION; NONHUMAN; RAT; SMALL INTESTINE DISEASE; SUCROSE BREATH TEST;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREATH TESTS; FEMALE; FIBROBLAST GROWTH FACTOR 7; FLUOROURACIL; INTESTINE, SMALL; MUCOSITIS; RATS; SUCRASE;

EID: 80052374420     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.5.15977     Document Type: Article

References (40)

1. AGA Report on Burden of Gastrointestinal Disease. Bethseda: The American Gastroenterological Assocication 2001.
2. Keefe D.M., Gibson R.J., Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 2004; 20:38-47; PMID: 15038516; DOI: 10.1053/j. soncn.2003.10.007.
3. Levy-Polack M.P., Sebelli P., Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist 1998; 18:189-93; PMID: 10219183; DOI: 10.1111/j.1754-4505.1998. tb01738.x.
4. Duncan M., Grant G. Oral and intestinal mucositis- causes and possible treatments. Aliment Pharmacol Ther 2003; 18:853-74; PMID: 14616150; DOI: 10.1046/j.1365-2036.2003.01784.x.
5. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 2004; 100:1995-2025; PMID: 15108222; DOI: 10.1002/cncr.20162.
6. Cool J.C., Dyer J.L., Xian C.J., Butler R.N., Geier M.S., Howarth GS. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 2005; 15:72-82; PMID: 15701575; DOI: 10.1016/j. ghir.2004.12.002.
7. Howarth G.S., Cool J.C., Bourne A.J., Ballard F.J., Read LC. Insulin-like growth factor-I (IGF-I) stimulates regrowth of the damaged intestine in rats, when administered following, but not concurrent with, methotrexate. Growth Factors 1998; 15:279-92; PMID: 9714912; DOI: 10.3109/08977199809017483.
8. Booth C., Booth D., Williamson S., Demchyshyn L.L., Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37:385-400; PMID: 15548172; DOI: 10.1111/j.1365-2184. 2004.00320.x.
9. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61:687-693; PMID: 11212269.
10. Gibson R.J., Bowen J.M., Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464-70; PMID: 15800945; DOI: 10.1002/ ijc.21082.
11. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-8; PMID: 15602019; DOI: 10.1056/NEJMoa040125.
12. auf demKeller U., Krampert M., Kumin A., Braun S., Werner S. Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Cell Biol 2004; 83:607-12; PMID: 15679105; DOI: 10.1078/0171-9335-00389.
13. Sasaki M., FitzGerald A.J., Mandir N., Berlanga-Acosta J., Goodlad RA. Keratinocyte growth factor and epidermal growth factor can reverse the intestinal atrophy associated with elemental diets in mice. Exp Physiol 2003; 88:261-7; PMID: 12621531; DOI: 10.1113/ eph8802466.
14. Awada A., Genot M.T., Klastersky J. Palifermin and chemotherapy-induced oral mucositis. N Engl J Med 2005; 352:1264-1265
15. Borges L., Rex K.L., Chen J.N., Wei P., Kaufman S., Scully S., et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapyinduced mucositis. Int J Radiat Oncol Biol Phys 2006; 66:254-62; PMID: 16904525; DOI: 10.1016/j. ijrobp.2006.05.025.
16. Zia-Amirhosseini P., Hurd D.D., Salfi M., Cheah T.C., Aycock J., Cesano A. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy 2007; 27:1353-60; PMID: 17896890; DOI: 10.1592/phco.27.10.1353.
17. Rzepecki P., Sarosiek T., Barzal J., Oborska S., Nurzynski P., Wasko A., et al. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience. J BUON 2007; 12:477-482; PMID: 18067205.
18. McDonnell A.M., Lenz KL. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother 2007; 41:86-94; PMID: 17190850; DOI: 10.1345/aph.1G473.
19. Byrne F.R., Farrell C.L., Aranda R., Rex K.L., Scully S., Brown H.L., et al. rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2002; 282:690-701; PMID: 11897629.
20. Miceli R., Hubert M., Santiago G., Yao D.L., Coleman T.A., Huddleston K.A., et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 1999; 290:464-471; PMID: 10381813.
21. Farrell C.L., Bready J.V., Rex K.L., Chen J.N., DiPalma C.R., Whitcomb K.L., et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933-939; PMID: 9500453.
22. Pelton N.S., Tivey D.R., Howarth G.S., Davidson G.P., Butler RN. A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 2004; 39:1015-6; PMID: 15513344; DOI: 10.1080/00365520410003416.
23. Tooley K.L., Saxon B.R., Webster J., Zacharakis B., McNeil Y., Davidson G.P., et al. A novel non-invasive biomarker for assessment of small intestinal mucositis in children with cancer undergoing chemotherapy. Cancer Biol Ther 2006; 5:1275-81; PMID: 17012839; DOI: 10.4161/cbt.5.10.3303.
24. Tooley K.L., Howarth G.S., Lymn K.A., Lawrence A., Butler RN. Oral ingestion of streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Ther 2006; 5:593-600; PMID: 16627985; DOI: 10.4161/ cbt.5.6.2659.
25. Howarth G.S., Tooley K.L., Davidson G.P., Butler RN. A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat. Cancer Biol Ther 2006; 5:1189-95; PMID: 16931906; DOI: 10.4161/cbt.5.9.3117.
26. Smith C.L., Geier M.S., Yazbeck R., Torres D.M., Butler R.N., Howarth GS. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 2008; 60:757-67; PMID: 19005975; DOI: 10.1080/01635580802192841.
27. Torres D.M., Tooley K.L., Butler R.N., Smith C.L., Geier M.S., Howarth GS. Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. Cancer Biol Ther 2008; 7:295-302; PMID: 18059190; DOI: 10.4161/ cbt.7.2.5332.
28. Estívariz C.F., Jonal C.R., Gu L.H., Diaz E.E., Wallace T.M., Pascal R.R., et al. Gut-trophic effects of keratinocyte growth factor in rat small intestine and colon during enteral refeeding. JPEN J Parenter Enteral Nutr 1998; 22:259-67; PMID: 9739027; DOI: 10.1177/0148607198022005259.
29. Clarke RM. Progress in measuring epithelial turnover in the villus of the small intestine. Digestion 1973; 8:161- 75; PMID: 4581925; DOI: 10.1159/000197311.
30. Jeppesen P.B. Clinical significance of GLP-2 in shortbowel syndrome. J Nutr 2003; 133:3721-3724; PMID: 14608103.
31. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124:105-12; PMID: 15544847; DOI: 10.1016/j.regpep.2004.07.009.
32. Washizawa N., Gu L.H., Gu L., Openo K.P., Jones D.P., Ziegler TR. Comparative effects of glucagon-like peptide- 2 (GLP-2), growth hormone (GH) and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J Parenter Enteral Nutr 2004; 28:399-409; PMID: 15568286; DOI: 10.1177/0148607104028006399.
33. Johnson W.F., DiPalma C.R., Ziegler T.R., Scully S., Farrell CL. Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. Vet Surg 2000; 29:17-27; PMID: 10653491; DOI: 10.1111/j.1532-950X.2000.00017.x.
34. Wright T.H., Yazbeck R., Lymn K.A., Whitford E.J., Cheah K.Y., Butler R.N., et al. The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther 2009; 8:923-9; PMID: 19276679; DOI: 10.4161/cbt.8.10.8146.
35. Goodlad R.A., Mandir N., Meeran K., Ghatei M.A., Bloom S.R., Playford RJ. Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration? Regul Pept 2000; 87:83-90; PMID: 10710291; DOI: 10.1016/ S0167-0115(99)00113-5.
36. Playford R.J., Marchbank T., Mandir N., Higham A., Meeran K., Ghatei M.A., et al. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol 1998; 184:316-22; PMID: 9614385; DOI: 10.1002/(SICI)1096- 9896(199803)184:3⟨316::AIDPATH3⟩3.0.CO;2-#.
37. Tomas F.M., Knowles S.E., Owens P.C., Read L.C., Chandler C.S., Gargosky S.E., et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochem J 1991; 276:547-554; PMID: 1710892.
38. Whitford E.J., Cummins A.G., Butler R.N., Prisciandaro L.D., Fauser J.K., Yazbeck R., et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 2009; 8:505-11; PMID: 19305160; DOI: 10.4161/cbt.8.6.7594.
39. Cheah K.Y., Howarth G.S., Yazbeck R., Wright T.H., Whitford E.J., Payne C., et al. Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther 2009; 8:382-90; PMID: 19305141; DOI: 10.4161/cbt.8.4.7453.
40. Ghoos Y.F., Maes B.D., Geypens B.J., Mys G., Hiele M.I., Rutgeerts P.J., et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104:1640-1647; PMID: 8500721.